Zhang Nan, Shi Junping, Shi Xiaoliang, Chen Wenting, Liu Junfeng
Department of Thoracic Surgery, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
Department of Medicine, OrigiMed Co. Ltd, Shanghai, People's Republic of China.
Onco Targets Ther. 2020 Dec 14;13:12797-12809. doi: 10.2147/OTT.S275688. eCollection 2020.
Esophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer in China and the 5-year mortality rate is up to 70%. Studies on the ESCC genetic landscape are needed to further explore clinical therapeutic strategies. In this study, we evaluated the genetic landscape of ESCC to aid the search for clinical therapeutic strategies.
A total of 225 ESCC patients were enrolled in this study. Deep sequencing of 450 cancer genes was performed on formalin-fixed paraffin-embedded tumor biopsies and matched blood samples from patients. Tumor mutational burden (TMB) was calculated using an algorithm developed in-house.
Our results showed that the most commonly mutated genes in ESCC were (96%), (46%), (44%), (44%), (44%), (31%), (26%), (24%), (18%), (16%), and (16%). We found that TMB correlated with patient drinking status. We identified mutations associated with sex, early ESCC, high TMB, and metastasis lymph nodes. mutations associated with sex ( = 0.035), tumor stage ( = 0.016), high TMB ( = 0.0072), and overall survival of patients ( = 0.0026). mutations associated with high TMB ( = 0.0016) and metastasis-positive lymph nodes ( = 0.027). These results suggested that and could be potential prognosis biomarkers for Chinese patients with ESCC. We also found that the number of positive lymph nodes was associated with disease-free survival. Clinical target gene analysis indicated that nearly half of Chinese ESCC patients might benefit from treatment with gene-specific target drugs.
Our study revealed the ESCC mutational landscape in 225 Chinese patients and uncovered the potential prognosis biomarker for Chinese patients with ESCC.
食管鳞状细胞癌(ESCC)是中国最常见的食管癌类型,5年死亡率高达70%。需要对ESCC的基因图谱进行研究,以进一步探索临床治疗策略。在本研究中,我们评估了ESCC的基因图谱,以辅助寻找临床治疗策略。
本研究共纳入225例ESCC患者。对患者的福尔马林固定石蜡包埋肿瘤活检组织及配对的血液样本进行450个癌症基因的深度测序。使用内部开发的算法计算肿瘤突变负荷(TMB)。
我们的结果显示,ESCC中最常发生突变的基因是(96%)、(46%)、(44%)、(44%)、(44%)、(31%)、(26%)、(24%)、(18%)、(16%)和(16%)。我们发现TMB与患者饮酒状况相关。我们鉴定出与性别、早期ESCC、高TMB和转移淋巴结相关的突变。与性别相关的突变(=0.035)、肿瘤分期(=0.016)、高TMB(=0.0072)以及患者总生存期(=0.0026)。与高TMB相关的突变(=0.0016)和转移阳性淋巴结(=0.027)。这些结果表明,和可能是中国ESCC患者潜在的预后生物标志物。我们还发现阳性淋巴结数量与无病生存期相关。临床靶基因分析表明,近一半的中国ESCC患者可能从基因特异性靶向药物治疗中获益。
我们的研究揭示了225例中国患者的ESCC突变图谱,并发现了中国ESCC患者潜在的预后生物标志物。